Items where authors include "Genge, A."
Article
Genge, A., Cedarbaum, J.M., Shefner, J. et al. (19 more authors) (2024) The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25 (3-4). pp. 382-387. ISSN 2167-8421
Howard, J.F. orcid.org/0000-0002-7136-8617, Bresch, S., Farmakidis, C. et al. (24 more authors) (2024) Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Therapeutic Advances in Neurological Disorders, 17. ISSN 1756-2864
Gwathmey, K.G. orcid.org/0000-0002-7589-8826, Corcia, P., McDermott, C.J. orcid.org/0000-0002-1269-9053 et al. (4 more authors) (2023) Diagnostic delay in amyotrophic lateral sclerosis. European Journal of Neurology, 30 (9). pp. 2595-2601. ISSN 1351-5101
Miller, T.M., Cudkowicz, M.E., Genge, A. et al. (23 more authors) (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. New England Journal of Medicine, 387 (12). pp. 1099-1110. ISSN 0028-4793
Shaw, P. orcid.org/0000-0002-8925-2567, Miller, T., Cudkowicz, M. et al. (7 more authors) (2022) Tofersen in adults with SOD1-ALS: phase 3 VALOR trial and open-label extension results. Journal of Neurology, Neurosurgery & Psychiatry, 93 (9). e2. ISSN 0022-3050
van Eijk, R.P.A., Beelen, A., Kruitwagen, E.T. et al. (16 more authors) (2021) A road map for remote digital health technology for motor neuron disease. Journal of Medical Internet Research, 23 (9). e28766. ISSN 1438-8871
Miller, T., Cudkowicz, M., Shaw, P.J. orcid.org/0000-0002-8925-2567 et al. (28 more authors) (2020) Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 383 (2). pp. 109-119. ISSN 0028-4793
van den Berg, L.H., Sorenson, E., Gronseth, G. et al. (20 more authors) (2019) Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 92 (14). e1610-e1623. ISSN 0028-3878